Myocardial Infarction Genes (MI-GENES) Study
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 12-001727
NCT ID: NCT01936675
Sponsor Protocol Number: 12-001727
About this study
This study is being done to better understand how genetic information might improve assessment of heart attack risk.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Patients between the ages of 45-70 years
- Patients who have participated in the Mayo Clinic Biobank or a previous research study at Mayo Clinic
- Patients who live in Southeast Minnesota
Exclusion Criteria:
- Taking statin or other lipid lowering medications
- Patients with a history of myocardial infarction, coronary artery disease, or other atherosclerotic medical conditions
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Iftikhar Kullo, M.D. |
Closed for enrollment |
|
More information
Publications
-
Susceptibility variants identified by genome-wide association studies (GWAS) have modest effect sizes. Whether such variants provide incremental information in assessing risk for common 'complex' diseases is unclear. We investigated whether measured and imputed genotypes from a GWAS dataset linked to the electronic medical record alter estimates of coronary heart disease (CHD) risk.
Read More on PubMed